Organon & Co. (OGN): Price and Financial Metrics
OGN Price/Volume Stats
| Current price | $17.86 | 52-week high | $24.79 |
| Prev. close | $17.87 | 52-week low | $10.84 |
| Day low | $17.81 | Volume | 2,129,500 |
| Day high | $18.24 | Avg. volume | 2,763,767 |
| 50-day MA | $17.90 | Dividend yield | 6.32% |
| 200-day MA | $17.24 | Market Cap | 4.57B |
OGN Stock Price Chart Interactive Chart >
Organon & Co. (OGN) Company Bio
Organon & Co. Organon & Co. is a science-based global pharmaceutical company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. Its women's health portfolio includes Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. Its operating segments include the Organon Products segment. The Organon Products segment is engaged in developing and delivering health solutions through its portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's products segment portfolio includes: Women's Health, Biosimilars and Established Brands. Women's Health contains contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing and elonva. The Company's Biosimilars portfolio consists of three immunology products: Brenzys, Renflexis and Hadlima; and two oncology products: Ontruzant and Aybintio.
Latest OGN News From Around the Web
Below are the latest news stories about ORGANON & CO that investors may wish to consider to help them evaluate OGN as an investment opportunity.
Organon To Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJERSEY CITY, N.J., December 21, 2023--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference, Tuesday January 9. |
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine MedicinesJERSEY CITY, N.J., December 18, 2023--Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe |
Organon To Present at the Piper Sandler 35th Annual Healthcare ConferenceJERSEY CITY, N.J., November 21, 2023--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST. |
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued groupFiling acceptance reinforces Samsung Bioepis and Organon’s commitment to provide better access to biologic medicines for patients in the United States INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today ann |
Organon Reports Results for the Third Quarter Ended September 30, 2023JERSEY CITY, N.J., November 02, 2023--Organon Reports Results for the Third Quarter Ended September 30, 2023 |
OGN Price Returns
| 1-mo | -0.45% |
| 3-mo | 16.99% |
| 6-mo | 16.92% |
| 1-year | -20.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 25.75% |
| 2023 | -45.12% |
| 2022 | -4.86% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
OGN Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...